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S_mmary Several studies have now shown that women with operable breast cancer undergoing tumour
excision during the luteal phase ofthe menstrual cycle have a better prognosis than those having surgery during
the follicular phase. As part of a prospective study of prognostic factors in breast cancer, blood was taken at
the time of surgery. Between 1975 and 1992 this was available from 289 premenopausal women within 3 days
of tumour excision. All were treated by either modified radical mastectomy or breast conservation including
axillary ckarance and the date of last menstrual period (LMP) was known in 239 (80%) cases. Blood samples
were assayed for both oestradiol (E2) and progesterone (P). Because ofthe wide inter-individual variation in E2
levels there was no clear relationship between E2 and LMP. However, using a running mean smoothing
technique the expected cyclical variation could be discemed. There was no significant association between E2
and survivaL Smoothing of the P data yielded a pattern similar to the normal hormone profile. Those cases
with a progesterone level of 4 ng ml-I or more had a significantly better survival than those with a level
<4 ng ml-'. This was especially clear in node-positive patients (P<0.01). The possibility ofmisclassification of
menstrual cycle status, because of misreported LMP, has been minimised by applying an independent
hormonal measurement (P) of cycle activity. This parameter will also identify women who may be undergoing
anovular cycles. Thus this study has confirmed that a raised level of progesterone at the time of tumour
excision is associated with an improvement in prognosis for women with operable breast cancer.
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Remission of advanced breast cancer following oophorect-
omy in premenopausal women was first reported nearly a
century ago (Beatson, 1896). It is now generally accepted that
ovarian hormones have an important role in the clinical
course of many human breast cancers. A previous study from
Guy's Hospital (Badwe et al., 1991) had indicated that the
timing of surgery within the menstrual cycle was an
important factor in determining both disease-free and overall
survival. Prognosis was significantly worse for patients
operated on between days 3 and 12 of the cycle, compared
with other times. This effect was more pronounced in patients
with histologically confirmed axillary nodal metastases but
was unrelated to the oestrogen receptor status of the primary
cancer.
Although some other centres reported similar findings
(Senie et al., 1991; Saad et al., 1994; Veronesi et al., 1994)
there have been other negative studies (Powles et al., 1991;
Sainsbury et al., 1991; Low et al., 1991). There are major
difficulties in comparing these published results partly
because of differences in timings used, errors in self-
reporting, anovular cycles and possible variations in
treatment. Despite this, a recent meta-analysis demonstrated
that overall there is a significant effect oftiming of surgery on
prognosis (Fentiman et al., 1994).
Because all the studies were based upon retrospective data,
Badwe et al. (1994) attempted to overcome these problems by
measuring oestradiol (E2) and progesterone (P) on stored
serum from 271 premenopausal patients operated upon
between 1975 and 1985. Taking a cut-off of > 1.5 ng ml-'
of P there was a significantly better prognosis in node-
positive cases with higher P levels. Further blood samples
were available from 200 other patients operated on between
1979 and 1992, and concentrations of both E2 and P were
assayed in these and combined with the previous results. This
report describes the influence of menstrual cycle on the
prognosis of an enlarged cohort of 471 premenopausal cases
of operable breast cancer.
Material and metKods
Patients
Between 1975 and 1992 a total of 1271 premenopausal
patients presented to Guy's Hospital Breast Unit with
unilateral operable invasive breast cancer. As part of a
study of prognostic factors blood had been taken from some
of these women. Serum was prepared from the blood and
stored at -20°C. In a previous report 271 samples were
analysed for E2 and P (Badwe et al., 1994). A further search
yielded 200 samples from different women, to give an
enlarged cohort of 471 cases. Of these 471 women, 289
(61%) had blood taken within 3 days of tumour excision.
Thus, an additional 79 evaluable cases were added to this
study. All were treated by either modified radical mastectomy
or breast conservation therapy comprising tumorectomy,
axillary clearance and radiotherapy.
Last menstrual period (LMP)
The date of the LMP, regularity and length of cycle were
available from the hospital notes of 239 of the 471 who had
blood taken.
Blood oestradiol and progesterone assays
E2 and P were measured using commerically available
radioimmunoassay kits (Diagnostic Products) and were
similar to those used and descri6ed previously (Badwe et
al., 1994). The determination of E2 was based on a double
antibody radioimmunoassay method using an '"I-labelled E2
ligand and polyethylene glycol-assisted second antibody to
separate bound from free ligand. The assay of P was based
on a solid-phase method in which the primary antibody was
bound to the walls of plastic tubes. The radioactive P was
labelled with '"I.
To estimate inter- and intra-assay variation, quality
control samples from prepared blood sample pools were
included in every batch of assays. In addition, 20% of the
serum samples were assayed in duplicate. In general the inter-
and intra-coefficient of variation was less than 10% for both
assays.
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Relapse-free and overall survival were calculated using the
method of Kaplan and Meier (1958) and significance of
comparisons determined using the log-rank test (Peto et al.,
1977). Multivariate analysis was performed using Cox's
proportional hazards model (Cox, 1972). A forward stepwise
inclusion procedure was used, with a P-value for entry of
variables of <0.05. Variables considered for the stepwise
procedure were age, tumour size, tumour histology (type and
grade), axillary nodal status, (number ofinvolved nodes) and
serum progesterone.
The smoothing of the E2 and P data was achieved with a
running mean method, using the STATA statistical comput-
ing package (Computing Resources Center, 1992), where
centred subsets of 70 observations were used for calculating
each smoothed (mean) value.
Results
Progesterone and oestradiol levels and menstrual status
Of the 461 patients, 289 had blood taken within 3 days of
diagnostic excisional biopsy and 234 had known dates of
LMP. From the total of 289 patients, 146 (51%) had
histologically negative lymph nodes following axillary
clearance. The mean perioperative P value of the 289 cases
was 3.7 ng ml-' (s.d. =4.3) with a range of 0.1-20 ng ml-'.
There were 140 patients with axillary lymph node metastases
and the mean P level for this group was 3.6 ng ml-I
(s.d. =3.9). Of the node-positive cases, 99 (71%) received
no systemic adjuvant therapy, 22 were given cyclophos-
phamide, methotrexate and 5-fluorouracil (CMF) and 13
(9%) were given melphalan (L-PAM). The remaining six
(4%) were treated by ovarian irradiation with or without
prednisolone. The P levels were plotted against the calculated
day of the cycle in the 234 women for whom LMP data were
available (Figure 1). In spite of the between-person variation
in P levels, it is clear that serum P concentration was higher
in the luteal phase of the cycle.
Smoothing of the data showed a cyclical change in serum
P similar to the expected pattern (Figure 1). Of the 76
patients who were putatively in the first 12 days of the cycle,
92% had P levels of 4 ng ml-' or less. In the 158 cases
calculated to be in the luteal phase (day 13 to day 30) 56%
had P levels in excess of 4 ng ml-'. The value of 4 ng ml-'
was chosen by inspection of Figure 1, to put as high a
proportion of values from the 0-12 day-in-cycle group into
the low/normal progesterone group without going beyond the
supposed normal range.
Whereas P levels conveniently help to divide the menstrual
cycle into a luteal and a non-luteal phase, E2 on the other
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hand, has a much more complex pattern (Figure 2). The E2
data, whether smoothed (Figure 2) or not, were not useful in
helping to assign the menstrual cycle status of patients.
Progesterone levels andprognosis
Comparison of patients having P levels > 1.5 ng ml-' with
those cases with blood levels lower than this showed that
there was no significant difference in survival (Figure 3).
However, when cases were dichotomised on the basis of P
levels of 4 ng ml-' and >4 ng ml-l it was found that
those with the higher P concentration had a significantly
better survival, as shown in Figure 4 (P=0.04). The
improved survival was particularly pronounced in the group
with nodal involvement and P levels >4 ng ml-' (P=0.01;
Figure 5). Survival in relation to absolute level of
progesterone was also compared for patients who had
surgery at both high- and low-risk times as determined by
LMP data. There was no direct relationship between survival
ofpatients in the low-risk group based on progesterone level,
nor in the high-risk group.
Table I shows the significant prognostic variables that
emerged from the multivariate analysis. The major prognostic
factors for survival in the entire group were, firstly, number
of involved nodes (RR=2.38, P<0.0001); secondly, tumour
type (RR=2.89, P<0.0001) and thirdly, serum progesterone
(RR= 1.76, P=0.027). All were significant for node-positive
cases but only tumour type (RR=3.45, P=0.008) was
significant in node-negative patients.
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Fugee 2 Oestradiol (E2) values for 239 patients with known
date of last menstrual period (LMP), with overlying smoothed
data.
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Fuge 1 Progesterone (P) levels for 239 patients with known
date oflast menstrual period (LMP), with smoothed progesterone
data.
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Fure 3 Overall survival of patients based on serum progester-
one (at time of surgery) < 1.5 ng ml-' and > 1.5 ng ml-1.
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Figue 4 Overall survival of patients based on progesterone
<4 ng ml-' and >4 ng ml-'.
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Figure 5 Overall survival of node-positive
progesterone <4 ng ml- and >4 ng ml-1.
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Table I Multivariate analysis showing significant prognostic variables
All patients Node positive Node negative
(n = 289) (n = 140) (n = 146)
RR (95% CI) RR (95% CI) RR (95% CI)
Node no.a 2.38 (1.83-3.09) 2.25 (1.33-3.8) -
P <0.0001 <0.01
Histologyb 2.89 (1.97-4.26) 2.82 (1.78-4.48) 3.45 (1.63-7.32)
P <0.001 <0.0001 0.008
ProgesteroneC 1.76 (1.04-2.96) 2.22 (1.15-4.29) 1.07 (0.44-2.58)
P 0.027 0.0002 0.88
aCategorisedO vs 1 -3 vs >4(three patients wereomitted because the numberof
involved nodes was unknown). Categorised according to Bloom and Richardson
grade with non-ductal types coded as grade II. cCategorised as 4ngml-1 vs
>4ngml-1. Age and tumour size were also considered as possible explanatory
variables, but were not significant in any ofthe analyses.
We have reported previously that women with operable
breast cancer undergoing surgery in the luteal phase of the
menstrual cycle have a better prognosis than those operated
upon at other times (Badwe et al., 1991). This finding has
been confirmed by others but not by all (Fentiman and
Gregory, 1993). More recently, the Milan group reported a
similar finding on a large series of patients (Veronesi et al.,
1994). The aim of this study was to explore more deeply this
phenomenon by assessing corpus luteum activity and
outcome. Firstly, the accuracy of self-reported LMP has
been assessed, together with the possible importance of
progesterone as a key agent in influencing prognosis.
The main finding of this study was that premenopausal
patients who underwent tumour excision when their blood
level of progesterone was >4 ng ml-' had a significantly
better overall survival than those treated at a time when P
levels were <4 ng ml-'. This effect was seen in all cases but
was most evident in those with axillary nodal involvement.
Within the high- and low-risk times there did not appear to
be a dose -response effect of level of progesterone on
prognosis. Whether progesterone per se is the reason for
this finding cannot be ascertained from the present data.
Possible mechanisms remain speculative.
The increase in proliferation of human breast cells in the
luteal phase of the cycle is intriguing (Anderson et al., 1982;
Masters et al., 1977), and the normal peritumoral cells might
be exerting an influence on the malignant cells. This would be
supported by the observation in our original report that the
effect of timing of surgery was equally large in patients with
oestrogen receptor-positive and oestrogen receptor-negative
tumours.
There is no evidence that there is a causal link between
mitotic activity and rise in level of blood P, and indeed
progesterone might be acting as a down-regulator of cell
proliferation since in endometrial tissue it has been shown
that 17fi-hydroxy-dehydrogenase is down-regulated by P.
This increases the conversion of E2 to the less biologically
active oestrone (El), while at the same time decreasing the
amount of oestradiol receptor and RNA message (Alexander
et al., 1990; Mandelond et al., 1991).
Finally, progestogens have been reported to down-regulate
IGF-l RNA message and content in breast cancer cell lines
(Papa et al., 1991). If progesterone is the active agent then it
might be that the concentration of this steroid is important
and it would be predicted that patients treated in the mid-
luteal phase, in which values of 20 ng ml-' occur, would
have a better prognosis. This was the case in our first study in
that when mortality rates were plotted against day of surgery,
the lowest death rate was seen between days 18 and 20
(Badwe et al., 1991).
In a previous study we used a progesterone level of
1.5 ng ml-' as cut-off between luteal and follicular phases.
However, in this larger study it was found that an
unacceptable proportion of women had P values greater
than 1.5 ng ml-' even though they were, based on LMP, in
the follicular stage of their cycle. Conversely, 42% ofpatients
who were putatively in the luteal phase, based on LMP, had
P levels <1.5 ng ml-'. One reason for this discrepancy in the
latter half of the cycle may be because in 65 cases the exact
cycle length was unknown and assumed to be 28 days. Thus,
some women with low progesterone levels may have been in
the early follicular stage of their next cycle. The chance of
laboratory errors is always possible but the inclusion of
routine quality controls and replicate samples in every assay
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batch makes this unlikely. Another possible explanation is
the occurrence of anovular cycles. Based on either blood
progesterone or urinary pregnanediol levels the incidence of
anovulatory cycles has been estimated to be in the region of
25%. Thus Wathen et al. (1984) reported that 9/39 (23%) of
'normal' women of reproductive age were experiencing
anovular cycles. Despite the apparent discrepancy between
LMP and P data, the classical menstrual profile of
progesterone was seen after the data were 'smoothed'. This
analytical technique also minimises the large between-person
variation in levels and the use of single blood specimens. This
result indicates that, in general, the LMP and progesterone
data are in accord but supports the view that knowledge of
both is necessary for establishing that patients are in the
luteal phase of the cycle.
Although the oestradiol data showed a classical cyclical
pattern after smoothing, there was a very large amount of
'noise' in these data with variations between patients
swamping the cycle effect. Thus, not surprisingly, there was
no discernible relationship between E2 levels and prognosis.
Unlike progesterone, E2 levels cannot therefore be used to
categorise patients according to menstrual cycle status, other
than the small proportion of mid-cycle cases with very high
levels.
The beneficial effect associated with elevated progesterone
levels at the time of surgery supports the hypothesis that
modification ofoestradiol activity by progesterone at the time
of surgery can significantly influence the prognosis of some
patients with early breast cancer. The mechanism has yet to
be elucidated but could have a profound impact on the future
treatment of operable breast cancer.
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